ABSTRACT
In the head and neck region, preoperative evaluation of the free flap volume is challenging. The current study validated preoperative three-dimensional (3D) virtual surgical simulation for soft tissue reconstruction by assessing flap volume and evaluated fat and muscle volume changes at follow-up in 13 head and neck cancer patients undergoing anterolateral craniofacial resection. Patients received 3D virtual surgical simulation, and the volume of the planned defects was estimated by surgical simulation. Following en bloc resection of the tumor, the defect in the skull base was covered using a rectus abdominis myocutaneous flap. Following surgery, computed tomography scans were acquired at day 1 and at 6 and 12 months. Virtual planned defect was on average 227 ml (range, 154-315) and was 10% smaller than the actual flap volume in patients without skin involvement of the tumor. Between day 1 and 12 months post-surgery, the volume of fat and muscle tissue in the free flap dropped by 9% and 58%, respectively. Our results indicate that 3D virtual surgical simulation provides essential information in determining the accurate volume of the required free flap for surgical defect repair and may thus help improve surgical planning and functional and esthetic outcome.
Subject(s)
Free Tissue Flaps , Head and Neck Neoplasms , Myocutaneous Flap , Plastic Surgery Procedures , Esthetics, Dental , Feasibility Studies , Head and Neck Neoplasms/diagnostic imaging , Head and Neck Neoplasms/surgery , HumansABSTRACT
Ureaplasma urealyticum could be a pathogen of non-gonococcal urethritis (NGU) in men. However, ureaplasma is often detected in men without NGU, and the proportion of cases possibly attributable to this pathogen is still undefined. We attempted to determine the bacterial loads of U. urealyticum significantly associated with NGU. The 16S rRNA genes of U. urealyticum were quantified by a real-time polymerase chain reaction-based assay in first-void urine (FVU) from 26 asymptomatic and 25 symptomatic men positive for U. urealyticum. The leucocyte counts in first-void urine (FVU) were determined as an objective measure of inflammatory response to ureaplasma in the hosts by automated quantitative urine particle analysis. Positive correlations were observed between copies of the 16S rRNA genes of U. urealyticum per ml and the leucocyte counts per µl in FVU (r = 0.49, p = 0.0003). Loads of ≥10(4) copies of the 16S rRNA gene of U. urealyticum/ml, corresponding to ≥5 × 10(3) cells of U. urealyticum/ml in FVU, were significantly associated with the presence of urethritis symptoms (p < 0.0001) and with higher leukocyte counts in FVU (p < 0.0001). The bacterial load of U. urealyticum, possibly of ≥5 × 10(3) cells of U. urealyticum/ml in FVU, could be significantly associated with the development of symptomatic NGU.
Subject(s)
Bacterial Load , Ureaplasma Infections/diagnosis , Ureaplasma urealyticum/isolation & purification , Urethritis/epidemiology , Adult , Humans , Leukocyte Count , Male , Polymerase Chain Reaction , RNA, Ribosomal, 16S/genetics , Real-Time Polymerase Chain Reaction , Retrospective Studies , Ureaplasma Infections/microbiology , Ureaplasma urealyticum/genetics , Urethritis/diagnosis , Urethritis/microbiology , UrinalysisABSTRACT
BACKGROUND: Brain metastases (BM) are a common in patients with lung cancer. Although whole-brain radiation therapy (WBRT) is the standard therapy, it may have a risk of decline in cognitive function of patients. In this study, we evaluated the efficacy of gefitinib alone without radiation therapy for the treatment of patients with BM from lung adenocarcinoma. MATERIALS AND METHODS: Eligible patients had BM from lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Gefitinib was given at 250 mg orally once a day until tumor progression or unacceptable toxicity. RESULTS: Forty-one patients were enrolled. The response rate was 87.8%. No patient experienced grade ≥4 toxicity. The median progression-free survival time was 14.5 months (95% CI, 10.2-18.3 months), and the median overall survival time was 21.9 months (95% CI, 18.5-30.3 months). In compared with L858R, exon 19 deletion was associated with better outcome of patients after treatment with gefitinib in both progression-free (p = 0.003) and overall survival (p = 0.025). CONCLUSION: Favorable response of BM to gefitinib even without irradiation was demonstrated. Exon 19 deletion was both a predictive and prognostic marker of patients with BM treated by gefitinib.
Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/secondary , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Adenocarcinoma/genetics , Adenocarcinoma/mortality , Adenocarcinoma of Lung , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Asian People , Brain Neoplasms/genetics , Brain Neoplasms/mortality , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Exons , Female , Gefitinib , Humans , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Male , Middle Aged , Mutation , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Quinazolines/administration & dosage , Quinazolines/adverse effects , Risk Factors , Treatment OutcomeABSTRACT
BACKGROUND: Chemokines and chemokine receptors not only have significant roles in cancer metastasis and tumorigenesis but also act as antitumour agents. The interaction between the Crk-like adaptor protein (CrkL), which is encoded by the CRKL gene, and non-receptor tyrosine kinase c-ABL is reported to transform many cells into malignant cells. We examined the effects of CC chemokine receptor 7 (CCR7), CCR7 ligands and CrkL and c-ABL in lung adenocarcinoma. METHODS: One hundred and twenty patients with lung adenocarcinoma were included in this historical cohort analysis. We examined CCR7 and CCR7 ligands and CrkL and c-ABL mRNA expressions in surgically resected lung adenocarcinoma specimens and evaluated their contribution to prognosis, and the relationship with epidermal growth factor receptor (EGFR) and TP53 mutations. RESULTS: High CCR7 mRNA expressions indicated better prognoses than those of the groups with low CCR7 mRNA expressions (P=0.007, HR=2.00, 95% CI of ratio: 1.22 -3.31). In lung adenocarcinoma, CrkL and c-ABL mRNAs were related to CCR7 mRNA expression (P<0.0001). CrkL and c-ABL mRNA expressions were influenced by EGFR mutations. A high expression of CCL19 was a good prognostic factor of lung adenocarcinoma. CONCLUSION: We propose that CCR7 and CCL19 are clinically good prognostic factors and that CCR7 is strongly related to CrkL and c-ABL kinase mRNA expression in lung adenocarcinoma.
Subject(s)
Adenocarcinoma/metabolism , Adenocarcinoma/mortality , Biomarkers, Tumor/metabolism , Chemokine CCL19/biosynthesis , Lung Neoplasms/metabolism , Lung Neoplasms/mortality , Receptors, CCR7/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adenocarcinoma/surgery , Adenocarcinoma of Lung , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Chemokine CCL19/genetics , ErbB Receptors/genetics , Female , Humans , Lung Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Nuclear Proteins/genetics , Prognosis , Proto-Oncogene Proteins c-abl/genetics , RNA, Messenger/biosynthesis , Receptors, CCR7/genetics , Survival Rate , Tumor Suppressor Protein p53/geneticsABSTRACT
AIMS: Recent studies have shown that fused-in-sarcoma (FUS) protein is a component of 'neuronal' intranuclear inclusion bodies (INIBs) in the brains of patients with intranuclear inclusion body disease (INIBD). However, the extent and frequency of FUS-immunoreactive structures in INIBD are uncertain. METHODS: We immunohistochemically examined the brain, spinal cord and peripheral ganglia from five patients with INIBD and five control subjects, using anti-FUS antibodies. RESULTS: In controls, the nuclei of both neurones and glial cells were intensely immunolabelled with anti-FUS and neuronal cytoplasm was weakly positive for FUS. In INIBD, neuronal and glial INIBs in the brain and spinal cord were positive for FUS. FUS-positive INIBs were also found in the peripheral ganglia. The proportion of FUS-positive neuronal INIBs relative to the total number of inclusion-bearing neurones ranged from 55.6% to 83.3% (average 73.2%) and that of FUS-positive glial INIBs ranged from 45.9% to 85.7% (average 62.7%). The nucleus and cytoplasm of inclusion-bearing neurones and glial cells showed no FUS immunoreactivity. CONCLUSIONS: These findings suggest that FUS is incorporated into INIBs in both neurones and glial cells and that loss of normal FUS immunoreactivity may result from reduced protein expression and/or sequestration within inclusions.
Subject(s)
Intranuclear Inclusion Bodies/metabolism , Neurodegenerative Diseases/metabolism , Neuroglia/metabolism , Neurons/metabolism , RNA-Binding Protein FUS/metabolism , Aged , Brain/immunology , Brain/metabolism , Brain/pathology , Female , Humans , Immunohistochemistry , Intranuclear Inclusion Bodies/immunology , Intranuclear Inclusion Bodies/pathology , Middle Aged , Neurodegenerative Diseases/immunology , Neurodegenerative Diseases/pathology , Neuroglia/immunology , Neuroglia/pathology , Neurons/immunology , Neurons/pathology , RNA-Binding Protein FUS/immunology , Spinal Cord/immunology , Spinal Cord/metabolism , Spinal Cord/pathologyABSTRACT
Two Arabidopsis thaliana extragenic mutations that suppress NaCl hypersensitivity of the sos3-1 mutant were identified in a screen of a T-DNA insertion population in the genetic background of Col-0 gl1 sos3-1. Analysis of the genome sequence in the region flanking the T-DNA left border indicated that sos3-1 hkt1-1 and sos3-1 hkt1-2 plants have allelic mutations in AtHKT1. AtHKT1 mRNA is more abundant in roots than shoots of wild-type plants but is not detected in plants of either mutant, indicating that this gene is inactivated by the mutations. hkt1-1 and hkt1-2 mutations can suppress to an equivalent extent the Na(+) sensitivity of sos3-1 seedlings and reduce the intracellular accumulation of this cytotoxic ion. Moreover, sos3-1 hkt1-1 and sos3-1 hkt1-2 seedlings are able to maintain [K(+)](int) in medium supplemented with NaCl and exhibit a substantially higher intracellular ratio of K(+)/Na(+) than the sos3-1 mutant. Furthermore, the hkt1 mutations abrogate the growth inhibition of the sos3-1 mutant that is caused by K(+) deficiency on culture medium with low Ca(2+) (0.15 mM) and <200 microM K(+). Interestingly, the capacity of hkt1 mutations to suppress the Na(+) hypersensitivity of the sos3-1 mutant is reduced substantially when seedlings are grown in medium with low Ca(2+) (0.15 mM). These results indicate that AtHKT1 is a salt tolerance determinant that controls Na(+) entry and high affinity K(+) uptake. The hkt1 mutations have revealed the existence of another Na(+) influx system(s) whose activity is reduced by high [Ca(2+)](ext).
Subject(s)
Arabidopsis Proteins , Cation Transport Proteins/metabolism , Plant Proteins/metabolism , Sodium/metabolism , Symporters/metabolism , Alleles , Arabidopsis/drug effects , Arabidopsis/genetics , Arabidopsis/metabolism , Calcium/metabolism , Cation Transport Proteins/genetics , Cations, Monovalent , Genes, Plant , Lithium , Mutagenesis , Phenotype , Plant Proteins/genetics , Plant Roots/metabolism , Potassium/metabolism , Sodium Chloride/pharmacology , Symporters/geneticsSubject(s)
Anti-Infective Agents/pharmacology , DNA Gyrase/genetics , DNA Topoisomerase IV/genetics , Mycoplasma Infections/microbiology , Mycoplasma Infections/urine , Mycoplasma/genetics , Urethritis/microbiology , Urethritis/urine , Anti-Infective Agents/therapeutic use , Fluoroquinolones , Humans , Male , Mycoplasma/drug effects , Mycoplasma Infections/drug therapy , Urethritis/drug therapyABSTRACT
OBJECTIVES: To present a case of fluoroquinolone treatment failure in urinary tract infection caused by Pseudomonas aeruginosa, accompanied by in vivo selection of the post-treatment isolate that showed decreased susceptibilities to fluoroquinolones, and to report fluoroquinolone resistance mechanisms in the post-treatment isolate. METHODS: A patient with urinary tract infection was treated with a suboptimal dose of a fluorinated quinolone, gatifloxacin. P. aeruginosa strains were isolated before and after fluoroquinolone treatment. The pretreatment and post-treatment isolates were examined for relatedness by arbitrarily primed polymerase chain reaction. For these isolates, the minimum inhibitory concentration of antimicrobial agents was determined and mutations in the target genes (gyrA and parC) and regulatory genes (mexR and nfxB) for drug efflux pumps were analyzed. RESULTS: Failure of fluoroquinolone treatment of urinary tract infection was observed. The post-treatment isolate, which was assumed to be isogenic to the pretreatment isolate, exhibited fourfold to 16-fold increases in the MIC of fluoroquinolones. In this isolate, a new mutation, not observed in the pretreatment isolate, was found only in the gyrA gene, resulting in an amino acid change of aspartic acid to asparagine in codon 87 of GyrA. CONCLUSIONS: The P. aeruginosa isolate that was initially susceptible to fluoroquinolones showed decreased susceptibility to fluoroquinolones after treatment with a suboptimal dose of one fluoroquinolone. In the post-treatment isolate, the alteration of GyrA would be responsible for the decreased susceptibility to fluoroquinolones. We should be aware that inappropriate use of fluoroquinolones could select such a strain harboring a quinolone resistance-associated alteration of DNA gyrase.
Subject(s)
Anti-Infective Agents/administration & dosage , Pseudomonas aeruginosa/classification , Pseudomonas aeruginosa/drug effects , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Aged , DNA, Bacterial/analysis , Drug Resistance, Microbial , Fluoroquinolones , Humans , Male , Microbial Sensitivity Tests , Mutation , Pseudomonas aeruginosa/genetics , Species Specificity , Treatment FailureABSTRACT
OBJECTIVES: To determine the pathologic significance of Staphylococcus saprophyticus in complicated urinary tract infections. METHODS: We performed a retrospective analysis of specimens demonstrating this organism based on a survey of 9980 urine specimens cultured in our clinic during an 11-year period. Forty-two specimens from 34 patients were positive for S. saprophyticus. RESULTS: S. saprophyticus was isolated in 13 women without underlying urologic disease, and their symptoms were compatible with acute cystitis or acute pyelonephritis. S. saprophyticus was isolated from 7 men and 14 women with underlying urologic disease. In most of these 21 patients, S. saprophyticus was thought not to be a true uropathogen but rather a colonizer, because the isolated organism was usually low in numbers and found with a low degree of pyuria, and the hosts were usually asymptomatic. However, 2 patients demonstrating S. saprophyticus colonization developed sepsis after urologic surgery. CONCLUSIONS: Although this organism is pathogenic in certain circumstances, suggesting the necessity of preoperative antimicrobial elimination, it is usually a colonizer in complicated urinary tract infections.
Subject(s)
Staphylococcus/isolation & purification , Urinary Tract Infections/microbiology , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Seasons , Sex Factors , Staphylococcus/classification , Staphylococcus/drug effects , Urinary Tract Infections/epidemiologyABSTRACT
Hemophilia A is a sex-linked recessive hereditary disease that is relatively rare and the number of patients with this disorder who undergo major surgery is limited. Although replenishing coagulation factors can allow hemophiliac patients to undergo similar surgery to that performed for patients without hemophilia, there have been few reports on major surgery and none on the resection of lung cancer in patients with hemophilia A. We recently performed completion pneumonectomy of the left lung in a 70-year-old man with hemophilia A, for squamous cell carcinoma in the residual left lung. The administration of a recombinant DNA coagulation factor VIII preparation allowed this operation to be successfully carried out. This case serves to demonstrate that the recombinant DNA coagulation factor VIII preparation described may enable us to safely perform major surgery on hemophiliac patients, since there is no risk of viral infection or any other adverse effects, such as deterioration of immunocompetence or hemolysis, which are occasionally encountered with human plasma-derived preparations.
Subject(s)
Carcinoma, Squamous Cell/surgery , Factor VIII/metabolism , Factor VIII/therapeutic use , Hemophilia A/complications , Lung Neoplasms/surgery , Pneumonectomy/methods , Aged , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/pathology , Hemophilia A/blood , Humans , Lung Neoplasms/blood , Lung Neoplasms/complications , Lung Neoplasms/pathology , Lymphatic Metastasis , Male , Neoplasm Recurrence, Local , Perioperative Care , Recombinant Proteins/therapeutic use , Treatment OutcomeABSTRACT
We describe a patient who had a complete and sustained response to interferon (IFN) therapy for chronic hepatitis C but developed small hepatocellular carcinoma (HCC) 80 months later. A 55-year-old Japanese man with hepatitis C virus (HCV) infection and histological features of chronic active hepatitis was treated with recombinant IFN alpha-2a, 9,000,000 U daily for 2 weeks followed by three times a week for 22 weeks. He successfully responded to IFN therapy with a normalization of serum alanine aminotransferase and continuous disappearance of serum HCV-RNA. However, 80 months after the cessation of IFN therapy, the patient's alpha-fetoprotein (AFP) level became elevated for the first time and HCC, 12 mm in diameter, was detected by routine ultrasonographic screening. Laparotomy revealed a small HCC with no metastasis, and the nontumorous liver demonstrated chronic inactive hepatitis. This case indicates the need for careful follow-up using ultrasonography and AFP testing for at least 7 years after completing IFN therapy in all patients with chronic hepatitis C, even if the patients have a complete response to the therapy.
Subject(s)
Carcinoma, Hepatocellular/etiology , Hepatitis C/complications , Liver Neoplasms/etiology , Carcinoma, Hepatocellular/diagnosis , Hepatitis C/therapy , Humans , Interferon-alpha/therapeutic use , Liver Neoplasms/diagnosis , Male , Middle Aged , alpha-Fetoproteins/metabolismABSTRACT
PURPOSE: We attempted to select increasingly fluoroquinolone-resistant strains of Neisseria gonorrhoeae in vitro and to assess whether selected mutants harbored alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV, which were analogous to those in fluoroquinolone-resistant clinical isolates. MATERIALS AND METHODS: A fluoroquinolone-susceptible strain was exposed to norfloxacin in vitro. Selected mutants were sequentially exposed to norfloxacin, and this procedure was repeated. For 11 mutants, minimum inhibitory concentrations (MICs) of antimicrobial agents were determined, and mutations in the region corresponding to the quinolone resistance-determining region (QRDR) of the Escherichia coli gyrA gene and the analogous region of the parC gene were analyzed. RESULTS: Mutants obtained in one step exhibited significantly increased MICs of norfloxacin, ofloxacin and ciprofloxacin and had a single amino acid change in GyrA. Two-step mutants exhibited significantly higher norfloxacin MICs. Three of four two-step selected strains had single amino acid changes in both GyrA and ParC. Three-step mutants exhibited further increases in fluoroquinolone MICs and were assigned to the ciprofloxacin-resistant category. Two had a double amino acid change in GyrA, and one had a double GyrA change and a single amino acid change in ParC. CONCLUSION: We selected fluoroquinolone-resistant strains that carried GyrA and ParC alterations analogous to those in clinical isolates. The serial accumulation of changes in the QRDR of GyrA and the analogous region of ParC was associated with a stepwise increase in fluoroquinolone resistance, although the development of additional alterations in other regions of GyrA and ParC or other mechanisms of fluoroquinolone resistance also might contribute to the enhancement in fluoroquinolone resistance. The clinical emergence of fluoroquinolone-resistant strains may be due to in-vivo stepwise selection of strains with genetic alterations in GyrA and ParC, as observed here in the in-vitro selection of fluoroquinolone-resistant mutants.
Subject(s)
Anti-Infective Agents/pharmacology , DNA Topoisomerases, Type II/genetics , Neisseria gonorrhoeae/drug effects , Aspartic Acid/genetics , Ciprofloxacin/pharmacology , DNA Gyrase , DNA Topoisomerase IV , DNA, Bacterial/genetics , Drug Resistance, Microbial/genetics , Escherichia coli/genetics , Genes, Bacterial/genetics , Glutamic Acid/genetics , Humans , Microbial Sensitivity Tests , Mutation/genetics , Neisseria gonorrhoeae/genetics , Norfloxacin/pharmacology , Ofloxacin/pharmacology , Selection, Genetic , Serine/geneticsABSTRACT
We performed a retrospective long-term study to evaluate the efficacy of intravesical instillation of Tokyo 172 strain Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder. Between 1989 and 1998, 42 patients with CIS of bladder underwent intravesical instillation of BCG. In the follow-up period from 6 to 116 months (mean: 37.3 months), the efficacy rate of intravesical BCG instillation for CIS of the bladder was 81.0%. Two patients died from the bladder cancer. The non-recurrence rate in patients with grade 2 carcinoma (19 cases) was not significantly different from that in those with grade 3 carcinoma (23 cases). However, the recurrence rate in patients with secondary CIS (15 cases) was significantly higher than in those with primary CIS (27 cases). The recurrence of CIS was observed in 7 of 42 cases. In 6 of 7 patients, CIS recurred within one year after treatment. Total cystectomy was performed in 10 of 42 patients, and pathological findings of muscle layer invasion were detected in 8 patients. Although side effects occurred in 33 patients (77.5%), no clinically significant side effects were observed. Our results suggest that intravesical BCG therapy may be useful for the treatment of CIS of the bladder.
Subject(s)
Adjuvants, Immunologic/administration & dosage , BCG Vaccine/administration & dosage , Carcinoma in Situ/therapy , Urinary Bladder Neoplasms/therapy , Administration, Intravesical , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
We summarized and reviewed published reports, including our studies, on the reverse transcription-polymerase chain reaction (RT-PCR) detection of micrometastatic prostate cancer cells in lymph nodes, bone marrow and peripheral blood. Some published data preliminarily suggest that the RT-PCR assay of micrometastatic prostate cancer cells may allow a more accurate assessment of lymph node and bone metastases of prostate cancer, and offer a presurgical prediction of the pathological stage of clinically localized disease. In addition, the RT-PCR assay may have a unique prognostic value in prostate cancer. However, controversy remains over the clinical significance of the RT-PCR assay. This assay could potentially develop into a diagnostic procedure for the clinical decision making in patients with prostate cancer. To establish the clinical significance of the RT-PCR assay, further optimized and standardized RT-PCR assay studies are needed, investigating large populations and involving long-term follow-up for the determination of any association between the results of the RT-PCR assay and specific clinical outcome.
Subject(s)
Lymph Nodes/pathology , Prostatic Neoplasms/pathology , Humans , Lymphatic Metastasis , Male , Prostate-Specific Antigen/genetics , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Tissue Kallikreins/geneticsABSTRACT
Our strategy for recurrent tumor after surgical resection for biliary malignancies, especially for hilar cholangiocarcinoma, is described. One hundred and thirty-three patients with hilar cholangiocarcinoma underwent curative resection in our department until November, 1998, and recurrent carcinomas have been pointed out in 73 patients (54.9%). The site of recurrence was peritoneum (21 cases), liver (16 cases), pre-caval and retro-duodenal space (15 cases), hepatic hilum (11 cases), lymph node (9 cases), bone (6 cases), sinus tract of percutaneous transhepatic biliary drainage (PTBD) (5 cases) and so on. Surgical resection was applied to recurrent carcinomas after careful evaluation, and 9 patients underwent surgical resection of the recurrent tumor: sinus tract of PTBD in the abdominal and/or chest wall (4 cases), lymph node (2 cases), liver (1 case), hepaticojejunostomy (1 case) and duodenum (1 case). There were three hospital death patients. Other six patients survived for 16 months on an average (11-20 months) after surgery for recurrent tumor. PTBD for recurrent cancer at the hepatic hilum and gastrojejunostomy for local recurrence around the duodenum improved quality of life of patients. Radiation therapy for bone metastasis or local recurrence at the hepatic hilum was sometimes very effective. Effect of systemic or transarterial chemotherapy is still unknown.
Subject(s)
Bile Ducts, Intrahepatic , Biliary Tract Neoplasms/surgery , Cholangiocarcinoma/secondary , Cholangiocarcinoma/surgery , Adult , Aged , Biliary Tract Neoplasms/pathology , Female , Humans , Male , Middle AgedABSTRACT
Pulmonary zygomycosis rarely occurs without pre-existing immunocompromised disease. A 72-year-old male was found to have a nodular shadow (3 cm x 4 cm) in the right S8 and S9 on a chest X-ray. Right lower lobectomy was performed and histological examination of the resected material demonstrated pulmonary zygomycosis. Hyphae stained positively not only with Grocott-Gomori methenamine silver staining, but also with an anti-Rhizopus oryzae polyclonal antibody.
Subject(s)
Lung Diseases, Fungal/diagnostic imaging , Rhizopus/isolation & purification , Zygomycosis/diagnostic imaging , Aged , Humans , Lung/microbiology , Lung/pathology , Lung Diseases, Fungal/pathology , Lung Diseases, Fungal/surgery , Male , Radiography , Zygomycosis/pathology , Zygomycosis/surgeryABSTRACT
A 29-year-old woman had been suffering from right back pain for 3 months. Chronic pulmonary thromboembolism was suspected and she was referred to our hospital. She presented with no risk factors for thromboembolism, and during the previous 6 months had lost 4 kg in body weight. Chest radiography showed nodular shadows in the lower field of the right lung. Contrast-enhanced computed tomography demonstrated a filling defect in the right pulmonary artery and nodular lesions in the lower field of the right lung, which were considered to be signs of pulmonary infarction. Absence of perfusion into the right lung was demonstrated by a perfusion scan. Right heart catheterization showed normal pressure in the pulmonary arteries, and pulmonary angiography showed an abrupt cutoff of the right pulmonary artery, which was similar to the finding of pulmonary thromboembolism. A transvenous catheter suction biopsy was performed in the right pulmonary artery and the histopathologic findings yielded a diagnosis of leiomyosarcoma. The patient underwent surgical resection under total cardiopulmonary bypass. A large tumor completely filled the right main pulmonary artery and invaded the posterior wall of the pulmonary trunk close to the left main pulmonary artery. Primary pulmonary leiomyosarcoma is a rare tumor and its prognosis is very poor. Radical surgical resection is the only effective treatment, but early diagnosis is very difficult. Transvenous catheter suction biopsy is a useful procedure for the early diagnosis of pulmonary artery sarcoma.
Subject(s)
Leiomyosarcoma/diagnosis , Pulmonary Artery , Vascular Neoplasms/diagnosis , Adult , Biopsy, Needle/methods , Catheterization, Peripheral , Diagnosis, Differential , Female , Humans , Leiomyosarcoma/pathology , Tomography, X-Ray Computed , Vascular Neoplasms/pathologyABSTRACT
A case of hypocontractile neurogenic bladder associated with agenesis of the corpus callosum is presented. Not only detrusor pressure but the urethral and anal pressures were also very weak. Although no abnormality could be detected on cervical, thoracic and lumbar magnetic resonance imaging and myelography, dysgenesis of the spinal cord or peripheral nerves associated with agenesis of corpus callosum was thought to be the cause of the neurogenic bladder.
ABSTRACT
A new method for measuring the refractive-index difference of a liquid has been developed. The liquid to be measured is contained in a 60-mm-diameter, cylindrical glass cell, and a He-Ne laser light is passed into the cell so that the laser light incidence fulfills the condition of minimum deviation. In this condition, the beam emerging from the cell has a fine interference fringe. The position of the interference fringe is read out as a marker to measure the deflection of the laser light. Directly reading the peak shift of the interference fringe makes it easy to obtain the refractive index difference of the liquid with a fairly high precision of at least 6 x 10(-6). Further high precision is potentially expected to be realized by use of an improved data analysis treatment of the overall interference fringe pattern.
ABSTRACT
The promoter of an anther tapetum-specific gene,Osg6B, was fused to aß-glucuronidase (GUS) gene and introduced into rice byAgrobacterium-mediated gene transfer. Fluorometric and histochemical GUS assay showed that GUS was expressed exclusively within the tapetum of anthers from the uninucleate microspore stage (7 days before anthesis) to the tricellular pollen stage (3 days before anthesis). This is the first demonstration of an anther-specific promoter directing tapetum-specific expression in rice.